Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)"'
Autor:
Jacobien R. Hilberink, Isabelle A. van Zeventer, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Gerwin Huls
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and
Externí odkaz:
https://doaj.org/article/71614de5d82b474e855269ada1ea2dee
Autor:
Löwenberg, Bob, Beck, Joachim, Graux, Carlos, van Putten, Wim, Schouten, Harry C., Verdonck, Leo F., Ferrant, Augustin, Sonneveld, Pieter, Jongen-Lavrencic, Mojca, von Lilienfeld-Toal, Marie, Biemond, Bart J., Vellenga, Edo, Breems, Dimitri, de Muijnck, Hilde, Schaafsma, Ron, Verhoef, Gregor, Döhner, Hartmut, Gratwohl, Alois, Pabst, Thomas, Ossenkoppele, Gert J., Maertens, Johan, for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), German Austrian AML Study Group (AMLSG), Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)
Publikováno v:
In Blood 1 April 2010 115(13):2586-2591
Autor:
Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, van Norden, Yvette, Biemond, Bart J, Schouten, Harry C, Spertini, Olivier, Vellenga, Edo, Graux, Carlos, Havelange, Violaine, de Greef, Georgine E, de Weerdt, Okke, Legdeur, Marie-Cecile J C, Kuball, Juergen, Kooy, Marinus van Marwijk, Gjertsen, Bjorn T, Jongen-Lavrencic, Mojca, van de Loosdrecht, Arjan A, van Lammeren-Venema, Daniëlle, Hodossy, Beata, Breems, Dimitri A, Chalandon, Yves, Passweg, Jakob, Valk, Peter J M, Manz, Markus G, Ossenkoppele, Gert J, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK)
Publikováno v:
Löwenberg, B, Pabst, T, Maertens, J, Van Norden, Y, Biemond, B J, Schouten, H C, Spertini, O, Vellenga, E, Graux, C, Havelange, V, De Greef, G E, De Weerdt, O, Legdeur, M C J C, Kuball, J, Van Marwijk Kooy, M, Gjertsen, B T, Jongen-Lavrencic, M, Van De Loosdrecht, A A, Van Lammeren-Venema, D, Hodossy, B, Breems, D A, Chalandon, Y, Passweg, J, Valk, P J M, Manz, M G & Ossenkoppele, G J 2017, ' Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML ', Blood, vol. 129, no. 12, pp. 1636-1645 . https://doi.org/10.1182/blood-2016-10-740613
Blood, 129(12), 1636-1645. The American Society of Hematology
Blood, 129(12), 1636-1645. American Society of Hematology
Blood, 129(12), 1636-1645. AMER SOC HEMATOLOGY
Blood, Vol. 129, No 12 (2017) pp. 1636-1645
Blood, 129(12), 1636. American Society of Hematology
Blood, 129(12), 1636-1645. The American Society of Hematology
Blood, 129(12), 1636-1645. American Society of Hematology
Blood, 129(12), 1636-1645. AMER SOC HEMATOLOGY
Blood, Vol. 129, No 12 (2017) pp. 1636-1645
Blood, 129(12), 1636. American Society of Hematology
Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be critically evaluated in younger adults in the frontline with standard chemotherapy. We compared 2 induction regimens in newly diagnosed patients ages
Autor:
Tettero JM; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Al-Badri WKW; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Ngai LL; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Bachas C; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Breems DA; Department of Hematology, Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium., van Elssen CHMJ; Department of Internal Medicine, Division of Hematology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands., Fischer T; Department of Hematology and Oncology, Otto von Guericke University Hospital Magdeburg, Magdeburg, Germany., Gjertsen BT; Department of Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway., van Gorkom GNY; Department of Internal Medicine, Division of Hematology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands., Gradowska P; The Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) Data Center, Department of Hematology, Erasmus Medical Center (MC) Cancer Institute, Rotterdam, Netherlands., Greuter MJE; Department of Epidemiology and Data Science, Amsterdam Univerisity Medical Centers, location Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Griskevicius L; Hematology, Oncology, Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos and Vilnius University, Vilnius, Lithuania., Juliusson G; Department of Hematology, Skanes University Hospital, Lund, Sweden., Maertens J; Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium., Manz MG; Department of Medical Oncology and Hematology, University Hospital, Zurich, Switzerland.; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Pabst T; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.; Department of Medical Oncology, Inselspital, University Hospital, Bern, Switzerland., Passweg J; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.; Department of Hematology, University Hospital, Basel, Switzerland., Porkka K; Department of Hematology, Helsinki University Hospital Cancer Center, Helsinki, Finland., Löwenberg B; Department of Hematology, Erasmus University Medical Center (MC) and Erasmus MC Cancer Institute, Rotterdam, Netherlands., Ossenkoppele GJ; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Janssen JJWM; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Cloos J; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands.
Publikováno v:
Frontiers in oncology [Front Oncol] 2022 Oct 10; Vol. 12, pp. 999822. Date of Electronic Publication: 2022 Oct 10 (Print Publication: 2022).
Autor:
Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research: Daniel den Hoed Cancer Center Rotterdam, The Netherlands. lowenberg@haed.azr.nl, Boogaerts MA, Daenen SM, Verhoef GE, Hagenbeek A, Vellenga E, Ossenkoppele GJ, Huijgens PC, Verdonck LF, van der Lelie J, Wielenga JJ, Schouten HC, Gmür J, Gratwohl A, Hess U, Fey MF, van Putten WL
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 1997 Dec; Vol. 15 (12), pp. 3496-506.